
@EORTC_HNCG_YI
@eortcy
ID: 1489605115019509766
04-02-2022 14:25:08
199 Tweet
191 Followers
232 Following


📣 Our review and metanalysis on IO in elderly HNSCC pts is now out! First paper coming from the EORTC HNCG YI group 🤓☺️ led by Viola Salvestrini and Petr Szturz. Check it out 👇🏻 frontiersin.org/journals/oncol…






Join us tomorrow and Friday for the ESMO - Eur. Oncology Virtual Plenary on HNSCC👇🏻 Full program and how to access: esmo.org/meeting-calend…



Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker in squamous cell carcinoma of the head and neck Institut Català d'Oncologia IGTP TTCC-GrupoTratamiento Tumores Cabeza y Cuello FETTCC Fundación E. Tto. Tumores Cabeza y Cuello



EORTC-1206: Double androgen blockade (bicalutamide + leuproreline) vs chemotherapy in AR+#salivaryglandcancer: ⛔️no benefit for frontline CAB, low response rates. Better to use combined or sequential approach? and what in HER2+ AR+ SGC? @EORTC_HNCG_YI ESMO - Eur. Oncology #ESMO2024


Did you know that around 700 000 people worldwide get #headandneckcancer, about 100 000 are attributed to #HPV infection. Prevention is the 🗝️to reduce cancer burden: stop tobacco 🚭& alcohol abuse, and increase vaccination rate 💉 Make Sense Campaign @EORTC_HNCG_YI




Congrats to Maryann Zhao on leading this NatureRevClinOncol review of #scRNASeq studies on #Tcell dynamics in #neoadjuvant ICI treated #HNSCC patients! Glenn J. Hanna, M.D. Robert Haddad Jonathan Schoenfeld R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) rdcu.be/d22hn

